“Michael’s contributions and unwavering determination to Dynavax have been important to the achievements of our enterprise. We are particularly fortuitous to have had his steerage more than the years and now as a strategic advisor to ensure a seamless transition to his successor,” commented Ryan Spencer, Main Govt Officer of Dynavax. “Kelly is an achieved fiscal chief with a deep being familiar with of company and commercial finance and will be an asset as we mature our business enterprise of building vaccines to aid avert the unfold of infectious health conditions. On behalf of the board and the other users of the government staff, it is a satisfaction to welcome Kelly to Dynavax.”
“This is an thrilling time to join Dynavax as it proceeds to make a primary vaccine enterprise, addressing urgent world wellbeing desires,” commented Kelly MacDonald. “I share the extensive-term motivation to Dynavax’ eyesight of collaboration, innovation and progress and glimpse forward to major the finance and accounting crew in executing the firm’s strategic and economical objectives.”
Ms. MacDonald joins Dynavax from Ironwood Prescription drugs exactly where she held roles of rising duty. In her final purpose at Ironwood Ms. MacDonald served as Chief Accounting Officer and Vice President, Finance in which she led the Firm’s corporate accounting and finance procedures, organization hazard management, treasury and cash allocation technique. While at Ironwood, she also held many other managerial roles, supplying finance and accounting assistance for the company’s strategic arranging, R&D portfolio management, global organization growth, merchandise launches and commercial execution. Prior to becoming a member of Ironwood, Kelly was a Supervisor in the Health and fitness Industries Assurance Practice at PricewaterhouseCoopers, principally serving consumers in lifetime sciences and technological innovation sectors.
Ms. MacDonald is a Licensed Community Accountant (CPA) and holds a Master of Enterprise Administration from the Isenberg College of Management at the College of Massachusetts and a Bachelor of Science in Accounting from Fairfield College.
Dynavax is a industrial stage biopharmaceutical corporation establishing and commercializing novel vaccines. The Firm’s to start with professional merchandise, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is permitted in the U.S. for prevention of an infection prompted by all regarded subtypes of hepatitis B virus in adults age 18 decades and more mature. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant by way of investigation collaborations and partnerships. Present-day collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For a lot more facts, go to www.dynavax.com and abide by the organization on LinkedIn.
Nicole Arndt, Senior Manager, Trader Relations
Derek Cole, President
Investor Relations Advisory Answers
Supply Dynavax Systems